Not seeing much to get excited over here.Revenue is on the higher end of guidance however margins are down 2% and EBIDTA is down from last quarter on higher revenue. Positive cash flow is looking good at just under 8 mil as well as the modest increase in cash position. Overall I consider this to be a status quo Q and nothing that will initiate any significant fresh buying tomorrow. I was hoping to see the sales team reflect in some more revenue uptick over last quarter on the Apparo side now that they have a sales team in place but that effect may not be shown until next Q. I'd be more interested in the conference call tomorrow than this quarterly report. The market needs guidance more than these mostly expected numbers and it would be good if management also gave some hints as to growth expectations on the apparo side, which will be key for me as to whether I invest any significant capital near term. The positive here of course is Viemed growth continues to be very solid. The other variable here is the split in which management has already passed the deadline to which they previous said there would already be a vote date announcement.